| Literature DB >> 35380024 |
Hye Ryeon Choi1, Sun Hyung Choi2, Namki Hong3, Yumie Rhee3, Jin Kyong Kim4, Cho Rok Lee4, Sang-Wook Kang4, Jandee Lee4, Jong Ju Jeong5, Kee-Hyun Nam4, Woong Youn Chung4.
Abstract
BACKGROUND: Normocalcemic primary hyperparathyroidism (NPHPT) was first described in 2008. It is defined as consistently elevated serum parathyroid hormone (PTH) levels with normal serum calcium (sCa) concentration, after excluding secondary causes of PTH elevation. However, the exact definition and management strategy for NPHPT remain controversial. We retrospectively investigated the clinicopathological features and short-term outcomes of NPHPT patients.Entities:
Keywords: Normocalcemic Hyperparathyroidism; Primary Hyperparathyroidism; Typical Hyperparathyroidism
Mesh:
Substances:
Year: 2022 PMID: 35380024 PMCID: PMC8980367 DOI: 10.3346/jkms.2022.37.e99
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Flow chart of inclusion of study sample.
eGFR = estimated glomerular filtration rate, TPHPT = typical primary hyperparathyroidism, PTH = parathyroid hormone, sCa = serum calcium, iCa = ionized calcium, ECPHPT = normocalcemic primary hyperparathyroidism with elevated ionized calcium.
Clinical characteristics of patients
| Variables | TPHPT (n = 158) | NPHPT (n = 122) | ||
|---|---|---|---|---|
| Age, yr | 59.3 ± 14.0 | 54.3 ± 13.1 | 0.002a | |
| Age < 50 yr | 33 (20.9%) | 40 (32.8%) | 0.025a | |
| Sex | 0.035a | |||
| Male | 38 (24.1%) | 17 (13.9%) | ||
| Female | 120 (75.9%) | 105 (86.1%) | ||
| BMD (n = 132, 99) | 0.008a | |||
| Normal | 15 (11.4%) | 27 (27.3%) | ||
| Osteopenia | 51 (38.6%) | 30 (30.3%) | ||
| Osteoporosis | 66 (50.0%) | 42 (42.4%) | ||
| T-score (lumbar) (n = 132, 99) | −2.4 ± 1.2 | −2.0 ± 1.3 | 0.024a | |
| Nephrolithiasis | 28 (17.7%) | 15 (12.3%) | 0.212 | |
| Bone fracture | 13 (8.2%) | 9 (7.4%) | 0.793 | |
| Preop PTH, pg/mL | 212.7 ± 219.3 | 115.9 ± 45.7 | 0.000a | |
| Preop sCa, mg/dL | 11.4 ± 1.1 | 9.9 ± 0.5 | 0.000a | |
| Preop iCa, mg/dL | 5.8 ± 0.4 | 5.4 ± 0.3 | 0.000a | |
| Preop P, mg/dL | 2.6 ± 0.5 | 2.9 ± 0.5 | 0.000a | |
| Preop 25-OH-Vit D, ng/mL | 19.3 ± 9.4 | 21.4 ± 9.2 | 0.065 | |
| 24hr urine calcium, mg/24hr | 324.3 ± 178.2 | 285.8 ± 159.9 | 0.105 | |
| eGFR, mL/min/1.73m2 | 80.4 ± 11.9 | 86.0 ± 8.2 | 0.000a | |
All continuous variables expressed as mean ± standard deviation.
TPHPT = typical primary hyperparathyroidism, NPHPT = normocalcemic primary hyperparathyroidism, BMD = bone mineral density, PTH = parathyroid hormone, sCa = serum calcium, iCa = ionized calcium, P = phosphorus, 25-OH-Vit D = 25-hydroxy-vitamin D, eGFR = estimated glomerular filtration rate.
aStatistical significance.
Intraoperative parathyroid hormone monitoring and pathology
| Variables | TPHPT (n = 158) | NPHPT (n = 122) | ||
|---|---|---|---|---|
| IOPTH change (%)a | 76.6 ± 19.2 | 72.5 ± 22.2 | 0.104 | |
| Miami criterion met | 143 (91.1%) | 107 (87.7%) | 0.430 | |
| No. of lesion | 0.004b | |||
| 1 | 151 (95.6%) | 109 (89.3%) | ||
| 2 | 4 (2.5%) | 13 (10.7%) | ||
| 3 | 3 (1.9%) | 0 (0) | ||
| Parathyroid size, cm | ||||
| Single lesion | 1.5 ± 0.7 | 1.4 ± 0.8 | 0.118 | |
| Multiple lesions | 1.1 ± 0.6 | 0.74 ± 0.4 | 0.011b | |
All continuous variables expressed as mean ± standard deviation.
TPHPT = typical primary hyperparathyroidism, NPHPT = normocalcemic primary hyperparathyroidism, IOPTH = intraoperative PTH monitoring.
Miami criterion; IOPTH drop ≥ 50% from the highest of either pre-incision or pre-excision level at 10 minutes after gland excision.
a% change from baseline; bStatistical significance.
Postoperative laboratory change
| Variables | PTH | Corrected serum Ca | Ionized Ca | Phosphorus | |||||
|---|---|---|---|---|---|---|---|---|---|
| Postop 3 mo | 0.996 | 0.259 | 0.473 | 0.054 | |||||
| TPHPT | 48.5 ± 29.8 | 9.1 ± 0.5 | 4.9 ± 0.7 | 3.4 ± 0.5 | |||||
| NPHPT | 48.5 ± 23.1 | 9.0 ± 0.5 | 4.9 ± 0.2 | 3.6 ± 0.5 | |||||
| Postop 12 mo | 0.716 | 0.020a | 0.437 | 0.028a | |||||
| TPHPT | 42.5 ± 19.9 | 8.9 ± 0.4 | 4.7 ± 0.3 | 3.4 ± 0.4 | |||||
| NPHPT | 41.6 ± 17.6 | 8.8 ± 0.7 | 4.8 ± 0.2 | 3.6 ± 0.4 | |||||
All continuous variables expressed as mean ± standard deviation.
TPHPT = typical primary hyperparathyroidism, NPHPT = normocalcemic primary hyperparathyroidism, PTH = parathyroid hormone.
aStatistical significance.
Comparisons between ECPHPT and NCPHPT
| Variables | ECPHPT (n = 95) | NCPHPT (n = 27) | ||
|---|---|---|---|---|
| Age, yr | 54.2 ± 12.1 | 54.6 ± 16.3 | 0.893 | |
| Sex, n | 0.881 | |||
| Male | 13 (13.7%) | 4 (14.8%) | ||
| Female | 82 (86.3%) | 23 (85.2%) | ||
| BMD (n = 80, 19) | 0.074 | |||
| Normal | 21 (26.3%) | 6 (31.6%) | ||
| Osteopenia | 28 (35.0%) | 2 (10.5%) | ||
| Osteoporosis | 31 (38.8%) | 11 (57.9%) | ||
| Nephrolithiasis, n | 13 (13.7%) | 2 (7.4%) | 0.381 | |
| Bone fracture, n | 7 (7.4%) | 2 (7.4%) | 0.995 | |
| Preop PTH, pg/mL | 120.6 ± 49.2 | 99.1 ± 24.5 | 0.002a | |
| Preop corrected sCa, mg/dL | 10.1 ± 0.3 | 9.5 ± 0.6 | 0.000a | |
| Preop iCa, mg/dL | 5.5 ± 0.2 | 4.9 ± 0.3 | 0.000a | |
| Preop phosphate, mg/dL | 2.8 ± 0.5 | 3.2 ± 0.5 | 0.000a | |
| Miami criterion met, n | 86 (90.5%) | 21 (77.8%) | 0.097 | |
| No. of lesion | 0.481 | |||
| Single | 86 (90.5%) | 23 (85.2%) | ||
| Double | 9 (9.5%) | 4 (14.8%) | ||
| Parathyroid size, cm | ||||
| Single | 1.5 ± 0.9 | 1.1 ± 0.5 | 0.003a | |
| Double | 0.6 ± 0.3 | 1.0 ± 0.4 | 0.012a | |
All continuous variables expressed as mean ± standard deviation.
ECPHPT = normocalcemic primary hyperparathyroidism with elevated ionized calcium, NCPHPT = normocalcemic primary hyperparathyroidism with normal ionized calcium, BMD = bone mineral density, PTH = parathyroid hormone.
aStatistical significance.
Comparisons between TPHPT and NCPHPT
| Variables | TPHPT (n = 158) | NCPHPT (n = 27) | ||
|---|---|---|---|---|
| Age, yr | 59.3 ± 14.0 | 54.6 ± 16.3 | 0.114 | |
| Age < 50 yr | 33 (20.9%) | 10 (37.0%) | 0.066 | |
| Sex, n | 0.290 | |||
| Male | 38 (24.1%) | 4 (14.8%) | ||
| Female | 120 (75.9%) | 23 (85.2%) | ||
| BMD (n = 132, 19) | 0.012a | |||
| Normal | 15 (11.4%) | 6 (31.6%) | ||
| Osteopenia | 51 (38.6%) | 2 (10.5%) | ||
| Osteoporosis | 66 (50.0%) | 11 (57.9%) | ||
| T-score (lumbar) (n = 132, 19) | −2.4 ± 1.2 | −2.2 ± 1.4 | 0.521 | |
| Nephrolithiasis, n | 28 (17.7%) | 2 (7.4%) | 0.179 | |
| Bone fracture, n | 13 (8.2%) | 2 (7.4%) | 0.885 | |
| Preop PTH, pg/mL | 212.7 ± 219.3 | 99.1 ± 24.5 | 0.008a | |
| Preop sCa, mg/dL | 11.4 ± 1.1 | 10.0 ± 0.7 | < 0.001a | |
| Preop iCa, mg/dL | 5.8 ± 0.4 | 4.9 ± 0.3 | < 0.001a | |
| Preop P, mg/dL | 2.6 ± 0.5 | 3.2 ± 0.5 | < 0.001a | |
| Preop 25-OH-Vit D, ng/mL | 19.3 ± 9.4 | 20.1 ± 8.6 | 0.682 | |
| 24hr urine calcium, mg/24hr | 324.3 ± 178.2 | 315.7 ± 169.3 | 0.848 | |
| eGFR, mL/min/1.73m2 | 80.4 ± 11.9 | 85.5 ± 7.8 | 0.006a | |
All continuous variables expressed as mean ± standard deviation.
TPHPT = typical primary hyperparathyroidism, NCPHPT = normocalcemic primary hyperparathyroidism with normal ionized calcium, BMD = bone mineral density, PTH = parathyroid hormone, sCa = serum calcium, iCa = ionized calcium, P = phosphorus, 25-OH-Vit D = 25-hydroxy-vitamin D, eGFR = estimated glomerular filtration rate.
aStatistical significance.